Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats

Brain Res. 1997 Apr 18;754(1-2):181-6. doi: 10.1016/s0006-8993(97)00075-9.

Abstract

The neuroprotective effects of pramipexole, a dopamine agonist, were investigated in 3-acetylpyridine (3-AP)-treated Wistar rats. Bromocriptine was used as a reference compound to compare the results obtained with pramipexole. A significant reduction (P < 0.01) in cerebellar cGMP and ATP was observed 96 h after treatment with 3-AP (500 micromol/kg, i.p.). Both pramipexole and bromocriptine significantly attenuated 3-AP-induced reduction in cerebellar cGMP and ATP. Consistent with the neurochemical effect, both pramipexole and bromocriptine prevented 3-AP-induced loss of motor coordination. 3-Acetylpyridine produced a significant (P < 0.01) loss of neurons in the inferior olivary nucleus. Treatment with pramipexole and bromocriptine partially, but significantly (P < 0.01), prevented the loss of inferior olivary neurons. There was no reduction in the temperature of the animals, indicating that hypothermia was not responsible for neuroprotection.

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Animals
  • Benzothiazoles
  • Body Temperature
  • Bromocriptine / pharmacology*
  • Cerebellum / drug effects
  • Cerebellum / metabolism*
  • Cyclic GMP / metabolism
  • Dopamine Agonists / pharmacology*
  • Male
  • Motor Activity / drug effects*
  • Neurons / drug effects
  • Neurons / pathology*
  • Neuroprotective Agents*
  • Neurotoxins
  • Olivary Nucleus / drug effects*
  • Olivary Nucleus / pathology
  • Pramipexole
  • Pyridines / toxicity*
  • Rats
  • Rats, Wistar
  • Thiazoles / pharmacology*

Substances

  • Benzothiazoles
  • Dopamine Agonists
  • Neuroprotective Agents
  • Neurotoxins
  • Pyridines
  • Thiazoles
  • 3-acetylpyridine
  • Bromocriptine
  • Pramipexole
  • Adenosine Triphosphate
  • Cyclic GMP